(Q34253488)

31 July 2017

3 references

25 April 2019

30 June 2019

20 November 2019

Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis (English)

1 reference

31 July 2017

3 references

25 April 2019

30 June 2019

20 November 2019

1 reference

20 November 2019

2

Sven Meuth

1 reference

31 July 2017

Martin Marziniak

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

3 September 2014

1 reference

31 July 2017

1 September 2014

3 references

25 April 2019

30 June 2019

20 November 2019

4 references

31 July 2017

25 April 2019

30 June 2019

20 November 2019

31

1 reference

31 July 2017

issue

9

1 reference

31 July 2017

page(s)

915-931

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-014-0149-1

31 July 2017

exact match

0 references

cites work

Defining the clinical course of multiple sclerosis: the 2013 revisions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

An update of teriflunomide for treatment of multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Immune therapy of multiple sclerosis--future strategies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Interferon β-1b and glatiramer acetate effects on permanent black hole evolution

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Improving compliance with interferon-beta therapy in patients with multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

History of modern multiple sclerosis therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Interferon-beta1b for multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Leflunomide in rheumatoid arthritis: recommendations through a process of consensus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4177103

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

6 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro™ 30G and Betacomfort® devices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis--results of the βPlus observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0149-1

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

21 January 2018

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS

1 reference

12 December 2020

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

12 December 2020

Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis

1 reference

12 December 2020

[Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices]

1 reference

12 December 2020

Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: A multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon β-1a for re

1 reference

12 December 2020

High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

10.1007/S12325-014-0149-1

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1035251633

0 references

Fatcat ID

release_d7c5cpnuvbaq5pee4lcahnchgq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d7c5cpnuvbaq5pee4lcahnchgq

24 November 2022

mapped directly with Wikidata item

PMC publication ID

4177103

1 reference

31 July 2017

1 reference